HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company has developed a new product using the same breakthrough imaging technology as used in its OxyVu™-1 system. HyperMed’s new product, called HyperView™, is FDA 510(k) cleared. HyperView is designed to deliver the same diagnostic information in a smaller, more portable configuration. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. technology has been in service since 2006 and has been shown in published clinical research to effectively assess oxyhemoglobin, deoxyhemoglobin and oxyhemoglobin saturation in superficial tissue for a number of key healthcare applications.The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market.